概括
神经息治疗解决了运动障碍患者和家属的复杂痛苦. 五大支柱框架有助于神经科医生系统地管理症状,提高护理质量.
科学领域:
- 神经学 神经学
- 抚慰性护理是一种缓解性护理.
背景情况:
- 运动障碍显著影响患者和家人,有未满足的息护理需求.
- 传统的护理模式往往未能解决非运动症状,心理社会支持和事先的护理计划.
- 息护理干预措施在改善这一群体的结果方面表现有希望.
研究的目的:
- 让读者熟悉与运动障碍相关的多维痛苦.
- 介绍神经息治疗护理框架和预防和治疗痛苦的技能.
- 强调将息治疗纳入神经病学实践的重要性.
主要方法:
- 对运动障碍的当前息护理方法的审查.
- 引入神经息治疗护理的五大支柱框架.
- 讨论将息护理技能纳入常规神经病学实践.
主要成果:
- 一个结构化的五支柱框架 (非运动症状,预先护理计划,心理社会/精神支持,护理伙伴支持,专业息护理转诊) 可以系统地解决痛苦.
- 这个框架可以通过查表格和模板集成到临床工作流程中.
- 神经科医生可以采用初级息护理技能来改善患者的治疗结果.
结论:
- 神经息治疗对于管理运动障碍患者的复杂需求至关重要.
- 五大支柱框架为神经病学家提供了一种实用的方法,以提供全面的息护理.
- 需要进一步的研究来优化神经科医生教育和息治疗的整合.
相关概念视频
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Continuing Care
1.8K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.8K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Peripheral Artery Disease III: Interprofessional Care
226
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
226
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K


